Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

468 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Use of micafungin as antifungal prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) in Spain (GETH-MIC).
López-Sánchez C, Valcárcel D, Gómez V, López-Jiménez J, Serrano D, Rubio V, Solano C, Vázquez L, Ruiz I; Grupo Español de Trasplante Hematopoyético (GETH). López-Sánchez C, et al. Among authors: solano c. Rev Esp Quimioter. 2020 Apr;33(2):110-115. doi: 10.37201/req/094.2019. Epub 2020 Feb 14. Rev Esp Quimioter. 2020. PMID: 32056418 Free PMC article.
GVHD prophylaxis with sirolimus-tacrolimus may overcome the deleterious effect on survival of HLA mismatch after reduced-intensity conditioning allo-SCT.
Parody R, Lopez-Corral L, Godino OL, Cadenas IG, Martinez AP, Vazquez L, Martino R, Martinez C, Solano C, Barba P, Valcarcel D, Caballero-Velazquez T, Marquez-Malaver FJ, Sierra J, Caballero D, Perez-Simón JA. Parody R, et al. Among authors: solano c. Bone Marrow Transplant. 2015 Jan;50(1):121-6. doi: 10.1038/bmt.2014.220. Epub 2014 Oct 13. Bone Marrow Transplant. 2015. PMID: 25310306 Clinical Trial.
Tacrolimus plus sirolimus with or without ATG as GVHD prophylaxis in HLA-mismatched unrelated donor allogeneic stem cell transplantation.
Kharfan-Dabaja MA, Parody R, Perkins J, Lopez-Godino O, Lopez-Corral L, Vazquez L, Caballero D, Falantes J, Shapiro J, Ortí G, Barba P, Valcárcel D, Esquirol A, Martino R, Piñana JL, Solano C, Tsalatsanis A, Pidala J, Anasetti C, Perez-Simón JA. Kharfan-Dabaja MA, et al. Among authors: solano c. Bone Marrow Transplant. 2017 Mar;52(3):438-444. doi: 10.1038/bmt.2016.269. Epub 2016 Nov 7. Bone Marrow Transplant. 2017. PMID: 27819684 Free article.
Phase IV open-label study of the efficacy and safety of deferasirox after allogeneic stem cell transplantation.
Vallejo C, Batlle M, Vázquez L, Solano C, Sampol A, Duarte R, Hernández D, López J, Rovira M, Jiménez S, Valcárcel D, Belloch V, Jiménez M, Jarque I; Subcommittee of Non-Infectious Complications of the Grupo Español de Trasplante Hematopoyético (GETH). Vallejo C, et al. Among authors: solano c. Haematologica. 2014 Oct;99(10):1632-7. doi: 10.3324/haematol.2014.105908. Epub 2014 Jul 4. Haematologica. 2014. PMID: 24997153 Free PMC article. Clinical Trial.
GvHD prophylaxis with tacrolimus plus sirolimus after reduced intensity conditioning allogeneic transplantation: results of a multicenter study.
Parody R, López-Corral L, Lopez-Godino O, Martinez C, Martino R, Solano C, Barba P, Caballero D, García-Cadenas I, Piñana JL, Marquez-Malaver FJ, Vazquez L, Esquirol A, Boluda JC, Sanchez-Guijo F, Pérez-Simon JA. Parody R, et al. Among authors: solano c. Bone Marrow Transplant. 2016 Nov;51(11):1524-1526. doi: 10.1038/bmt.2016.163. Epub 2016 Jun 13. Bone Marrow Transplant. 2016. PMID: 27295268 Free article. No abstract available.
Severe infections after allogeneic peripheral blood stem cell transplantation: a matched-pair comparison of unmanipulated and CD34+ cell-selected transplantation.
Martino R, Rovira M, Carreras E, Solano C, Jorge S, De La Rubia J, Caballero MD, de Oteyza JP, Zuazu J, Moraleda JM, Ojeda E, Ferrá C, Serrano D, De La Cámara R, Urbano-Ispízua A, Brunet S; AlloPBSCT and Infectious/Non-infectious Complications Subcommittes of the Grupo Español de Trasplante Hematopoyético (GETH). Martino R, et al. Among authors: solano c. Haematologica. 2001 Oct;86(10):1075-86. Haematologica. 2001. PMID: 11602414
Administration of recombinant human granulocyte colony-stimulating factor to normal donors: results of the Spanish National Donor Registry. Spanish Group of Allo-PBT.
de la Rubia J, Martínez C, Solano C, Brunet S, Cascón P, Arrieta R, Alegre A, Bargay J, de Arriba F, Cañizo C, López J, Serrano D, Verdeguer A, Torrabadella M, Díaz MA, Insunza A, de la Serna J, Espigado I, Petit J, Martínez M, Benlloch L, Sanz M. de la Rubia J, et al. Among authors: solano c. Bone Marrow Transplant. 1999 Oct;24(7):723-8. doi: 10.1038/sj.bmt.1701977. Bone Marrow Transplant. 1999. PMID: 10516674
Single-unit umbilical cord blood transplantation from unrelated donors in patients with hematological malignancy using busulfan, thiotepa, fludarabine and ATG as myeloablative conditioning regimen.
Sanz J, Boluda JC, Martín C, González M, Ferrá C, Serrano D, de Heredia CD, Barrenetxea C, Martinez AM, Solano C, Sanz MA, Sanz GF; Grupo Español de Trasplante Hematopoyético y Terapia Celular (GETH). Sanz J, et al. Among authors: solano c. Bone Marrow Transplant. 2012 Oct;47(10):1287-93. doi: 10.1038/bmt.2012.13. Epub 2012 Feb 13. Bone Marrow Transplant. 2012. PMID: 22327127 Clinical Trial.
Disparity for the minor histocompatibility antigen HA-1 is associated with an increased risk of acute graft-versus-host disease (GvHD) but it does not affect chronic GvHD incidence, disease-free survival or overall survival after allogeneic human leucocyte antigen-identical sibling donor transplantation.
Gallardo D, Aróstegui JI, Balas A, Torres A, Caballero D, Carreras E, Brunet S, Jiménez A, Mataix R, Serrano D, Vallejo C, Sanz G, Solano C, Rodríguez-Luaces M, Marín J, Baro J, Sanz C, Román J, González M, Martorell J, Sierra J, Martín C, de la Cámara R, Grañena A; GvHD Subcommittee of the Grupo Español de Trasplante Hemapoyético (GETH). Gallardo D, et al. Among authors: solano c. Br J Haematol. 2001 Sep;114(4):931-6. doi: 10.1046/j.1365-2141.2001.03013.x. Br J Haematol. 2001. PMID: 11564088 Free article.
Reduced-intensity conditioning reduces the risk of severe infections after allogeneic peripheral blood stem cell transplantation.
Martino R, Caballero MD, Canals C, San Miguel J, Sierra J, Rovira M, Solano C, Bargay J, Pérez-Simon J, León A, Sarrá J, Brunet S, de la Cámara R; alloPBSCT and Infectious/nonifectious Complications Subcommittees of the Grupo Español de Transplante Hematopoyético (GETH). Martino R, et al. Among authors: solano c. Bone Marrow Transplant. 2001 Aug;28(4):341-7. doi: 10.1038/sj.bmt.1703150. Bone Marrow Transplant. 2001. PMID: 11571505
468 results